The study gathers perceptions from medical oncologists and pathologists on topics such as awareness and current utilisation of pan-cancer tests, perceived advantages and disadvantages and drivers and barriers to use. In addition, it incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test. The detailed information collected includes: brand used, reason for testing, reasons for brand choice, treatment impact, test outcome, satisfaction with test, and more. Further expansion of the study to Asia-Pacific markets is planned for the coming months.
Commented Pieter De Richter, Head of Syndicated Real World Evidence in APAC/MENA for Ipsos Healthcare:
Pan-cancer testing is a rapidly growing, continually evolving and extremely dynamic market segment. While the US has been leading the charge when it comes to the adoption of innovative Next Generation Sequencing panels for anti-cancer treatment selection, the APAC region represents a huge opportunity for the adoption of these panels. With the launch of the study in Australia, we are now able to provide molecular diagnostics businesses and pharmaceutical companies with robust insights into the drivers for and barriers to the usage of pan-cancer testing panels, as well as detailed usage metrics, within this important region.
Ipsos Healthcare Launches MS Patient Community Panel
Ipsos Healthcare, the global healthcare business of Ipsos, has announced the launch of its syndicated Multiple Sclerosis (MS) Patient Community Panel. This latest offer is part of the Ipsos Healthcare Global Patient Centre of Excellence, launched in 2018.